Abstract
Dendritic cells-based immunotherapy requires the differentiation of these cells from precursor cells, monocytes. Monocytes constitute about 10% of the mononuclear cells present in peripheral blood, which represents a limited amount when considering the need for doses of immunotherapy in the order of about 1047 viable cells. In this sense, the monitoring of cell yield, as well as the deter…